A recent review of pivotal cancer drug trials suggests that CVD and adverse cardiovascular outcomes are underreported in studies of new cancer therapies, despite an increasing risk of cardiotoxicity in oncological drugs.

Research out of Ireland suggests end-of-life care needs will nearly double over the next three decades, corresponding to an increase of 84% by 2046.

Despite other quality of life improvements, heart patients supported by left ventricular assist devices face “severely impaired” exercise capacity, according to a study published online in JACC: Heart Failure.

Lab-growing cardiomyocytes have been transplanted into a human patient for the first time in medical history, according to a report from the Japan Times.

Scientists have uncovered a potential new treatment for heart failure with preserved ejection fraction (HFpEF)—and it’s one that already exists.

A cross-structural analysis published in Mayo Clinic Proceedings this January independently links diabetes to the development of heart failure, suggesting diabetic cardiomyopathy is a real—and growing—issue in the U.S.

Drugmaker AstraZeneca announced Jan. 6 that its SGLT2 inhibitor dapagliflozin, sold commercially as Farxiga, had been granted Priority Review by the FDA for patients with heart failure with reduced ejection fraction.

Diagnosed cases of chronic heart failure are expected to number 32 million by 2028, according to a report from analytics company GlobalData.